Flag of the European Union EU Clinical Trials Register Help

Clinical trials for T-cell growth factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: T-cell growth factor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-006229-23 Sponsor Protocol Number: PTCLS-IDE Start Date*: 2022-04-07
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas.
    Medical condition: peripheral T Cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003622 ATLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003700-44 Sponsor Protocol Number: BGB-A317-207 Start Date*: 2018-06-21
    Sponsor Name:BeiGene, Ltd. c/o BeiGene USA, Inc.
    Full Title: A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms
    Medical condition: Relapsed or Refractory Mature T- and NK-cell Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003946-17 Sponsor Protocol Number: FIL_PTCL_BV Start Date*: 2015-09-15
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patients
    Medical condition: RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T CELL LYMPHOMA (PTCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000883-27 Sponsor Protocol Number: Rif_CVID_260611 Start Date*: 2013-08-16
    Sponsor Name:Oslo University hospital
    Full Title: EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
    Medical condition: Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005382-79 Sponsor Protocol Number: FIL-BBV Start Date*: 2015-09-15
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30 + peripheral T-cell lymphoma in first salvage setting: the BBV regimen.
    Medical condition: Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10012877 Diffuse large cell lymphoma (Peripheral T-cell lymphoma unspecified) (Working Formulation) recurrent LLT
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000586-38 Sponsor Protocol Number: THIO-SM Start Date*: 2007-12-21
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS
    Medical condition: PATIENTS AFFECTED BY MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052785 HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021994-35 Sponsor Protocol Number: A4001098 Start Date*: 2011-06-30
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003683-54 Sponsor Protocol Number: OSHO #76 Start Date*: 2008-06-18
    Sponsor Name:GMIHO Gesellschaft für medizinische Innovation/Hämatologie und Onkologie mbH
    Full Title: Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbest...
    Medical condition: Patients suffering from leukemia (acute or chronic), receiving allogenic blood stem cell transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003280-35 Sponsor Protocol Number: 2017BN003 Start Date*: 2017-11-22
    Sponsor Name:UZ Brussel
    Full Title: AMENDMENT TITLE: Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01 in combination with intravenou...
    Medical condition: Patients with injectable metastases from histologically confirmed solid tumors who have failed standard-of-care life prolonging therapeutic options will be invited to participate in this clinical t...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000763-33 Sponsor Protocol Number: 20160283 Start Date*: 2017-12-01
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versu...
    Medical condition: Steroid Refractory Chronic Graft versus Host Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002879-17 Sponsor Protocol Number: 20160370 Start Date*: 2019-06-18
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003429-32 Sponsor Protocol Number: ImbruVeRCHOP-Trial Start Date*: 2017-02-09
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”
    Medical condition: untreated CD20-positive DLBCL-like aggressive Non-Hodgkin’s lymphoma, 61-80 years of age with unfavorable risk profile (IPI ≥ 2)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005562-38 Sponsor Protocol Number: M2011-238 Start Date*: 2012-11-13
    Sponsor Name:Miltenyi Biotec GmbH
    Full Title: A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in chi...
    Medical condition: Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012717-22 Sponsor Protocol Number: UCL/08/0167 Start Date*: 2010-01-13
    Sponsor Name:University College London
    Full Title: UKALL14 - A randomized trial for adults with newly diagnosed acute lymphoblastic leukemia
    Medical condition: Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-001587-13 Sponsor Protocol Number: RC21_0169 Start Date*: 2021-10-01
    Sponsor Name:CHU de Nantes
    Full Title: A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse.
    Medical condition: Elderly patients with multiple myeloma at first relapse
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000528-39 Sponsor Protocol Number: TAK-676-1002 Start Date*: 2023-03-20
    Sponsor Name:Takeda Development Center Americas, Inc. (TDC Americas)
    Full Title: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Ad...
    Medical condition: Solid Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003016-27 Sponsor Protocol Number: GCT3013-05 Start Date*: 2021-04-06
    Sponsor Name:Genmab A/S
    Full Title: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Medical condition: B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 11:38:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA